Drug intelligence / Profile preview

adagrasib + cetuximab

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

Adagrasib + cetuximab is a combination therapy consisting of adagrasib, an irreversible selective KRAS G12C inhibitor, and cetuximab, an anti-EGFR (epidermal growth factor receptor) antibody. This combination therapy targets KRAS G12C-mutated colorectal cancer, showing enhanced efficacy compared to adagrasib monotherapy. The combination works by inhibiting the KRAS G12C mutation while simultaneously blocking EGFR signaling, providing a dual mechanism to suppress cancer cell growth and proliferation.

Brand names: KRAZATI + cetuximabKRAZATI + Erbitux

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)

Beyond the preview

Go deeper on adagrasib + cetuximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on adagrasib + cetuximab.

Explore the full profile